PD-1 blockade with monoclonal antibodies has demonstrated promising response rates (65–87%) and long-term remissions in a subgroup of poor prognosis patients with relapsed and refractory cHL [28,29,30,31]. This evidence concerns the gene PDCD1 and classic Hodgkin lymphoma.